1. Market Research
  2. > Pathology
63 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

NHL: Follicular Lymphoma Forecast and Market Analysis (FL) to 2026

  • $ 22000
  • January 2019
  • 510 pages

NHL: Follicular Lymphoma Forecast and Market Analysis (FL) to 2026 CONTENTS ## FORECAST: FOLLICULAR LYMPHOMA (Published on ## January 2019) ## OVERVIEW ## RECENT FORECAST UPDATES ## MARKET DYNAMICS ## FORECAST AND FUTURE TRENDS ## MARKET DEFINITION AND METHODOLOGY ## PRIMARY

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034, Pharma Intelligence

  • $ 22000
  • October 2018
  • 475 pages

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034, Pharma Intelligence Table of Contents (Forecast, Treatment, Epidemiology Datapacks included) ## FORECAST: DIFFUSE LARGE B-CELL LYMPHOMA (Published on ## October 2018) ## OVERVIEW ## RECENT FORECAST UPDATES

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

NHL: Follicular Lymphoma Forecast and Market Analysis to 2025

  • $ 22000
  • April 2018
  • 229 pages

NHL: Follicular Lymphoma Forecast and Market Analysis to 2025 TABLE OF CONTENTS Forecast, Treatment, Epidemiology Datapacks included) & nbsp; ## FORECAST: FOLLICULAR LYMPHOMA (Published on ## April 2016) ## OVERVIEW ## EXECUTIVE SUMMARY ## MARKET OVERVIEW AND TRENDS ## METHODOLOGY

  • Cancer
  • Lymphoma
  • European Union
  • Japan
  • United States

NHL: Mantle Cell Lymphoma Disease Coverage Forecast and Market Analysis to 2034

  • $ 22000
  • April 2018
  • 196 pages

NHL: Mantle Cell Lymphoma Disease Coverage Forecast and Market Analysis to 2034 TABLE OF CONTENTS & nbsp; (Forecast, Treatment and Epidemiology Datapacks included) & nbsp; ## FORECAST: MANTLE CELL LYMPHOMA (Published on ## April 2016) ## OVERVIEW ## EXECUTIVE SUMMARY ## MARKET

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034

  • $ 22000
  • April 2018
  • 162 pages

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034 TABLE OF CONTENTS & nbsp; (Forecast, Treatment, Epidemiology Datapacks included) & nbsp; ## FORECAST: DIFFUSE LARGE B-CELL LYMPHOMA (Published on ## August 2016) ## OVERVIEW ## EXECUTIVE SUMMARY ## MARKET OVE

  • Cancer
  • Lymphoma
  • European Union
  • Japan
  • United States

Betalutin

  • $ 10000
  • January 2019
  • 17 pages

CD## is highly expressed in B cells and B-cell lymphomas.

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

Aliqopa

  • $ 10000
  • January 2019
  • 18 pages

Aliqopa CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Aliqopa : NHL: Follicular lymphoma (FL) LIST OF FIGURES ## Figure ##: Aliqopa for follicular lymphoma – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Aliqopa for follicular

  • Cancer
  • Lymphoma
  • Pathology
  • Therapy
  • European Union

umbralisib

  • $ 10000
  • January 2019
  • 26 pages

umbralisib CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## umbralisib : NHL: Follicular lymphoma (FL) ## umbralisib : NHL: Diffuse large B-cell lymphoma (DLBCL) LIST OF FIGURES ## Figure ##: Umbralisib for follicular lymphoma – SWOT analysis ## Figure ##: Datamo

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

lisocabtagene maraleucel

  • $ 10000
  • January 2019
  • 30 pages

lisocabtagene maraleucel CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## lisocabtagene maraleucel : NHL: Follicular lymphoma (FL) ## lisocabtagene maraleucel : NHL: Diffuse large B-cell lymphoma (DLBCL) LIST OF FIGURES ## Figure ##: Lisocabtagene maraleucel for follicula

  • Cancer
  • Lymphoma
  • Medical Biotechnology
  • Pathology
  • European Union

Yescarta

  • $ 10000
  • January 2019
  • 19 pages

Yescarta CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Yescarta : NHL: Follicular lymphoma (FL) ## Yescarta : NHL: Diffuse large B-cell lymphoma (DLBCL) LIST OF FIGURES ## Figure ##: Yescarta for follicular lymphoma – SWOT analysis ## Figure ##: Datamonitor H

  • Cancer
  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • European Union

Revlimid

  • $ 10000
  • January 2019
  • 56 pages

Revlimid CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Revlimid : NHL: Follicular lymphoma (FL) ## Revlimid : NHL: Diffuse large B-cell lymphoma (DLBCL) ## Revlimid : Multiple myeloma ## Revlimid : NHL: Mantle cell lymphoma (MCL) LIST OF FIGURES ## Figur

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • Japan

NHL: Diffuse large Bcell lymphoma

  • $ 5000
  • May 2016
  • 219 pages

Immunophenotyping also needs to be robust enough to distinguish the disease from other lymphomas which resemble DLBCL in morphology, such as mantle cell lymphoma and Burkitt' s lymphoma.

  • Cancer
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • European Union

NHL: Follicular lymphoma

  • $ 5000
  • April 2016
  • 252 pages

NHL: Follicular lymphoma Disease Coverage | Treatment: Follicular Lymphoma practices.

  • Healthcare
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • European Union

NHL: Mantle cell lymphoma

  • $ 5000
  • April 2016
  • 214 pages

Lymphoma Association (2016) Mantle cell lymphoma.

  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • European Union

MOR208

  • $ 10000
  • October 2018
  • 17 pages

MOR## CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## MOR## : NHL: Diffuse large B-cell lymphoma (DLBCL) LIST OF FIGURES ## Figure ##: MOR## for diffuse large B-cell lymphoma – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary for MOR## i

  • Lymphoma
  • Medical Biotechnology
  • Therapy
  • European Union
  • United States

polatuzumab vedotin

  • $ 10000
  • October 2018
  • 18 pages

polatuzumab vedotin CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## polatuzumab vedotin : NHL: Diffuse large B-cell lymphoma (DLBCL) LIST OF FIGURES ## Figure ##: Polatuzumab vedotin for diffuse large B-cell lymphoma – SWOT analysis ## Figure ##: Datamonitor Healthcare’

  • Lymphoma
  • Medical Biotechnology
  • Monoclonal Antibody
  • Therapy
  • European Union

Selinexor

  • $ 10000
  • October 2018
  • 32 pages

Selinexor CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## selinexor : NHL: Diffuse large B-cell lymphoma (DLBCL) ## selinexor : Multiple myeloma LIST OF FIGURES ## Figure ##: Selinexor for diffuse large B-cell lymphoma – SWOT analysis ## Figure ##: Datamonitor Healthcar

  • Cancer
  • Lymphoma
  • European Union
  • Japan
  • United States

Blincyto

  • $ 10000
  • October 2018
  • 25 pages

Blincyto CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Blincyto : NHL: Diffuse large B-cell lymphoma (DLBCL) ## Blincyto : Acute lymphoblastic leukemia (ALL) LIST OF FIGURES ## Figure ##: Blincyto for diffuse large B-cell lymphoma – SWOT analysis ## Figure ##: Datamon

  • Biopharmaceutical
  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • European Union

Bavencio

  • $ 10000
  • October 2018
  • 82 pages

Bavencio CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Bavencio : NHL: Diffuse large B-cell lymphoma (DLBCL) ## Bavencio : Non-small cell lung cancer (NSCLC) ## Bavencio : Gastric cancer ## Bavencio : Head and neck cancer ## Bavencio : Ovarian cancer ## Bavencio : Bladde

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • Japan

Gazyva

  • $ 10000
  • January 2019
  • 40 pages

Gazyva CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Gazyva : Chronic lymphocytic leukemia (CLL) ## Gazyva : NHL: Follicular lymphoma (FL) ## Gazyva : NHL: Mantle cell lymphoma (MCL) LIST OF FIGURES ## Figure ##: Datamonitor Healthcare’s drug assessment summary of

  • Lymphoma
  • Medical Biotechnology
  • Monoclonal Antibody
  • Therapy
  • European Union
View report >

Global Oncology Market

  • October 2018
  • 16 pages

Lymphoma Colorectal cancer Melanoma Breast cabozantinib lenvatinib nivolumab abemaciclib ado-trastuzumab emtansine neratinib palbociclib ribociclib cobimetinib dabrafenib nivolumab pembrolizumab sonidegib ra ## dichloride eribulin olaratumab trabectedin necitumumab nivolumab osimertinib pe

  • Lymphoma
  • Oncology
  • Therapy
  • European Union
  • World

Biotechnology Markets January 2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on